ArticleThe Lancet. Oncology2024

Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study.

Dai Maruyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.